Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma

The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. Pre-clinical testing of a microcontrol...

Full description

Bibliographic Details
Main Authors: Carolin Golla, Mayas Bilal, Annika Dwucet, Nicolas Bader, Jenson Anthonymuthu, Tim Heiland, Maximilian Pruss, Mike-Andrew Westhoff, Markus David Siegelin, Felix Capanni, Christian Rainer Wirtz, Richard Eric Kast, Marc-Eric Halatsch, Georg Karpel-Massler
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/16/4123
id doaj-ff1ac6cf968846c59e41530251643439
record_format Article
spelling doaj-ff1ac6cf968846c59e415302516434392021-08-26T13:35:53ZengMDPI AGCancers2072-66942021-08-01134123412310.3390/cancers13164123Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in GlioblastomaCarolin Golla0Mayas Bilal1Annika Dwucet2Nicolas Bader3Jenson Anthonymuthu4Tim Heiland5Maximilian Pruss6Mike-Andrew Westhoff7Markus David Siegelin8Felix Capanni9Christian Rainer Wirtz10Richard Eric Kast11Marc-Eric Halatsch12Georg Karpel-Massler13Department of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Mechatronics and Medical Engineering, Ulm University of Applied Sciences, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Pediatric and Adolescent Medicine, Ulm University Medical Center, 89075 Ulm, GermanyDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY 10032, USADepartment of Mechatronics and Medical Engineering, Ulm University of Applied Sciences, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyIIAIG Study Center, Burlington, VT 05408, USADepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyDepartment of Neurological Surgery, Ulm University Medical Center, 89081 Ulm, GermanyThe purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. Pre-clinical testing of a microcontroller-based device emitting light of 405 nm wavelength in combination with exposure to 5-ALA (PDT) and the Bcl-2/Bcl-xL inhibitor ABT-263 (navitoclax) was performed in human established and primary cultured glioblastoma cells as well as glioma stem-like cells. We applied cell count analyses to assess cellular proliferation and Annexin V/PI staining to examine pro-apoptotic effects. Western blot analyses and specific knockdown experiments using siRNA were used to examine molecular mechanisms of action. Bcl-2/Bcl-xL inhibition synergistically enhanced apoptosis in combination with PDT. This effect was caspase-dependent. On the molecular level, PDT caused an increased Noxa/Mcl-1 ratio, which was even more pronounced when combined with ABT-263 in a Usp9X-independent manner. Our data showed that Bcl-2/Bcl-xL inhibition increases the response of glioblastoma cells toward photodynamic therapy. This effect can be partly attributed to cytotoxicity and is likely related to a pro-apoptotic shift because of an increased Noxa/Mcl-1 ratio. The results of this study warrant further investigation.https://www.mdpi.com/2072-6694/13/16/4123glioblastoma5-aminolevulinic acidphotodynamic therapyABT-263navitoclaxBcl-xL
collection DOAJ
language English
format Article
sources DOAJ
author Carolin Golla
Mayas Bilal
Annika Dwucet
Nicolas Bader
Jenson Anthonymuthu
Tim Heiland
Maximilian Pruss
Mike-Andrew Westhoff
Markus David Siegelin
Felix Capanni
Christian Rainer Wirtz
Richard Eric Kast
Marc-Eric Halatsch
Georg Karpel-Massler
spellingShingle Carolin Golla
Mayas Bilal
Annika Dwucet
Nicolas Bader
Jenson Anthonymuthu
Tim Heiland
Maximilian Pruss
Mike-Andrew Westhoff
Markus David Siegelin
Felix Capanni
Christian Rainer Wirtz
Richard Eric Kast
Marc-Eric Halatsch
Georg Karpel-Massler
Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
Cancers
glioblastoma
5-aminolevulinic acid
photodynamic therapy
ABT-263
navitoclax
Bcl-xL
author_facet Carolin Golla
Mayas Bilal
Annika Dwucet
Nicolas Bader
Jenson Anthonymuthu
Tim Heiland
Maximilian Pruss
Mike-Andrew Westhoff
Markus David Siegelin
Felix Capanni
Christian Rainer Wirtz
Richard Eric Kast
Marc-Eric Halatsch
Georg Karpel-Massler
author_sort Carolin Golla
title Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
title_short Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
title_full Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
title_fullStr Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
title_full_unstemmed Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
title_sort photodynamic therapy combined with bcl-2/bcl-xl inhibition increases the noxa/mcl-1 ratio independent of usp9x and synergistically enhances apoptosis in glioblastoma
publisher MDPI AG
series Cancers
issn 2072-6694
publishDate 2021-08-01
description The purpose of this study was to assess in vitro whether the biological effects of 5-aminolevulinic acid (5-ALA)-based photodynamic therapy are enhanced by inhibition of the anti-apoptotic Bcl-2 family proteins Bcl-2 and Bcl-xL in different glioblastoma models. Pre-clinical testing of a microcontroller-based device emitting light of 405 nm wavelength in combination with exposure to 5-ALA (PDT) and the Bcl-2/Bcl-xL inhibitor ABT-263 (navitoclax) was performed in human established and primary cultured glioblastoma cells as well as glioma stem-like cells. We applied cell count analyses to assess cellular proliferation and Annexin V/PI staining to examine pro-apoptotic effects. Western blot analyses and specific knockdown experiments using siRNA were used to examine molecular mechanisms of action. Bcl-2/Bcl-xL inhibition synergistically enhanced apoptosis in combination with PDT. This effect was caspase-dependent. On the molecular level, PDT caused an increased Noxa/Mcl-1 ratio, which was even more pronounced when combined with ABT-263 in a Usp9X-independent manner. Our data showed that Bcl-2/Bcl-xL inhibition increases the response of glioblastoma cells toward photodynamic therapy. This effect can be partly attributed to cytotoxicity and is likely related to a pro-apoptotic shift because of an increased Noxa/Mcl-1 ratio. The results of this study warrant further investigation.
topic glioblastoma
5-aminolevulinic acid
photodynamic therapy
ABT-263
navitoclax
Bcl-xL
url https://www.mdpi.com/2072-6694/13/16/4123
work_keys_str_mv AT carolingolla photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT mayasbilal photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT annikadwucet photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT nicolasbader photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT jensonanthonymuthu photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT timheiland photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT maximilianpruss photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT mikeandrewwesthoff photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT markusdavidsiegelin photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT felixcapanni photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT christianrainerwirtz photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT richarderickast photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT marcerichalatsch photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
AT georgkarpelmassler photodynamictherapycombinedwithbcl2bclxlinhibitionincreasesthenoxamcl1ratioindependentofusp9xandsynergisticallyenhancesapoptosisinglioblastoma
_version_ 1721194549079965696